A prospective case-control pilot study to evaluate the possible effect of a probiotic mixture in the improvement of symptoms, the reduction in the number of days of hospitalization and the increase in the percentage of patients with negative PCR after infection with the coronavirus SARS-CoV-2.
In this study, the investigators hypothesize a positive effect of probiotic on the gut
microbiome that could led to produce a less severe clinical evolution of the disease.
Dietary Supplement: Probiotic
Oral daily capsule containing probiotic strains with maltodextrin as excipient, administrated for 30 days.
Inclusion Criteria:
- Patients with a confirmed diagnosis of SARS-Cov.2 infection using the PCR and that
require admission to the hospitalization area.
Exclusion Criteria:
- Inability or refusal to sign informed consent.
- Allergy or intolerance to the intervention product or its components.
Hospital Universitario del Vinalopó
Elche, Alicante, Spain
Hospital Universitario de Torrevieja
Torrevieja, Alicante, Spain
Vicente Navarro, Principal Investigator
Hospital universitario del Vinalopo, Elche, Spain